Friday, September 4, 2015 Last update: 5:03 AM - Covering Large & Obscure Tech Companies Since 1996

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target

Companies mentioned in this article: Vista Partners LLC

SAN FRANCISCO, CA -- (Marketwired) -- 06/11/14 -- Vista Partners announced today that it has updated coverage on Soligenix, Inc. (OTCBB: SNGX) and maintained its twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases.

Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.4B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis." Mr. Silver continues, "Soligenix also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($270M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis, a potentially billion dollar market." Mr. Silver continues, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $33 million in active government contract and grant funding still available to support its associated research programs through 2018." Mr. Silver concludes, "Company Insiders exercised options to purchase common shares in May 2014 according to Form 4's filed at Also, in the past two years Company Insiders have purchased or exercised options to purchase shares and no Company Insiders have sold shares during the same period."

To download a FREE copy of the Soligenix, Inc. research report, please visit and click the "download research" icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.

Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website or click here.


Vista Partners
Email Contact